14 completed, 6 unknown, 5 not yet recruiting, 2 active not recruiting. 33 Phase 2, 7 Phase 1.
Follow Institut Paoli-Calmettes: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer Pembrolizumab - Early Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 84 | 2026-11-01 | 2026-10-05 |
| FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML fludarabine and treosulfan - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 77 | 2026-10-10 | 2026-05-20 |
| De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Recruiting | Institut Paoli-Calmettes | 50 | 2026-02-04 | 2026-03-13 |
| Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE Dasatinib - Acute Myeloid Leukemia | Phase 2 | Suspended | Institut Paoli-Calmettes | 35 | 2024-05-22 | 2026-10-01 |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers M1774, Fulvestrant injection - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 57 | 2024-05-01 | 2024-03-29 |
| PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM Thymoglobulin Injectable Product - Hematological Malignancy | Phase 2 | Unknown | Institut Paoli-Calmettes | 27 | 2024-03-31 | 2024-02-20 |
| A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr Niraparib Oral Product - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 72 | 2023-03-01 | 2022-08-29 |
| Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract Patients receiving neoadjuvant therapy before radical nephrectomy - Urothelial Carcinoma, Cancer | Phase 2 | Unknown | Centre Hospitalier Universitaire de Nīmes | 50 | 2021-09-29 | 2023-05-30 |
| Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning Busulfan Injection - Acute Leukemia, Mielodysplasic Syndrome | Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 82 | 2020-11-01 | 2020-11-17 |
| Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML prophylactic donor lymphocyte infusion (DLI) - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Institut Paoli-Calmettes | 124 | 2020-09-07 | 2026-09-29 |
| Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Avelumab, Radiotherapy - Non-muscle-invasive Bladder Cancer | Phase 2 | Unknown | Institut Paoli-Calmettes | 67 | 2020-06-15 | 2019-05-16 |
| Eribulin in Brain Metastases From HER2-negative Breast Cancer Eribulin - Metastatic Breast Cancer | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2019-02-26 | 2020-05-06 | |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer Pembrolizumab Injection, neoadjuvant EC-paclitaxel chemotherapy - Inflammatory Breast Cancer | Phase 2 | Active not recruiting | Institut Paoli-Calmettes | 52 | 2018-08-29 | 2025-09-12 |
| Prospective Evaluation of the Ablation Therapy With Bipolar Radio Frequency for Nonresectable Bile Duct Cancer Ablation Therapy - Nonresectable Bile Duct Cancer | Phase 2 | Completed | Institut Paoli-Calmettes | 20 | 2018-03-22 | 2023-06-23 |
| Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer Apalutamide - Low Risk Prostate Cancer | Phase 2 | Completed | Institut Paoli-Calmettes | 93 | 2017-04-28 | 2026-10-14 |
| A Study to Assess the Efficacy and Safety of ABTL0812 ABTL0812 in combination with paclitaxel and carboplatin - Endometrial Cancer, Squamous Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Ability Pharmaceuticals SL | 103 | 2016-12-01 | 2023-02-22 |
| Histological Response Rate After Mastectomy and Immediate Breast Reconstruction at the End of Neoadjuvant Chemotherapy and Radiotherapy Immediate mammary reconstruction, Chemotherapy, Radiation therapy - Breast Cancer | Phase 2 | Unknown | Institut Paoli-Calmettes | 101 | 2016-01-27 | 2023-07-03 |
| Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases Allogeneic transplant conditioning - Hematological Diseases | Phase 2 | Completed | Institut Paoli-Calmettes | 33 | 2014-09-01 | 2019-01-24 |
| Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF) - Oesophageal Cancer, Rectal Cancer | Phase 2 | Completed | Institut Paoli-Calmettes | 29 | 2014-04-01 | 2017-03-03 |
Showing 20 of 33. Sign in to see all of them.
Leukemia, Myeloid, Acute (8) · Breast Neoplasms (7) · Congenital Abnormalities (3) · Leukemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Myelodysplastic Syndromes (3) · Neoplasms, Plasma Cell (3) · Burkitt Lymphoma (2) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Chronic-Phase (2) · Lymphoma (2)
Busulfan (6) · Antilymphocyte Serum (3) · Paclitaxel (3) · fludarabine phosphate (3) · Cyclophosphamide (2) · Radiotherapy (2) · Rituximab (2) · fludarabine (2) · pembrolizumab (2) · ABTL0812 (1) · Amsacrine (1) · Anthracyclines (1) · Azacitidine (1) · Bevacizumab (1) · Carboplatin (1)
France (25) · Spain (1)
Didier Blaise, MD (3) · Ana Oaknin (1) · Anthony Goncalves, Pr (1) · Norbert Vey, MD (1)
PMID 26885686, PMID 28950146, PMID 33330051, PMID 34781168, PMID 35122700, PMID 35293148, PMID 37698632, PMID 39039449, PMID 39951246
2016 (2), 2025 (2), 2018 (1)